Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $.001 per share
-
Shares outstanding
-
31.8M
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
461K
-
Shares change
-
+147K
-
Total reported value, excl. options
-
$1.31M
-
Value change
-
+$417K
-
Number of buys
-
7
-
Number of sells
-
-3
-
Price
-
$2.84
Significant Holders of Moleculin Biotech, Inc. - Common Stock, par value $.001 per share (MBRX) as of Q3 2024
17 filings reported holding MBRX - Moleculin Biotech, Inc. - Common Stock, par value $.001 per share as of Q3 2024.
Moleculin Biotech, Inc. - Common Stock, par value $.001 per share (MBRX) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 461K shares
of 31.8M outstanding shares and own 1.45% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (290K shares), VANGUARD GROUP INC (71.4K shares), LPL Financial LLC (36.1K shares), GEODE CAPITAL MANAGEMENT, LLC (21.8K shares), BlackRock, Inc. (12.5K shares), RENAISSANCE TECHNOLOGIES LLC (11K shares), TRUIST FINANCIAL CORP (10.5K shares), ATTICUS WEALTH MANAGEMENT, LLC (3.33K shares), Tower Research Capital LLC (TRC) (1.81K shares), and Newbridge Financial Services Group, Inc. (1.37K shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.